Sol-Gel (SLGL) intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results